Selux Diagnostics is developing a Next-Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. Earlier, better-informed treatment decisions will save lives, improve patient outcomes, decrease hospital lengths of stay and hospital-acquired infections, and help combat the global antibiotic resistance epidemic. 

Biotechnology

Selux Diagnostics

Steve Lufkin

Adam Steel

Nathan Purmort

Mallory Webb

Liz Kinnal

Kassi Cox Whale, MBA

Jingzi Sherman

Donna Gasper

Andrea Clostio

Alex D.

Mark Rando, ITIL

John Wilson

Jack Percoskie

Eric Stern

Aleksandar Vacic

The executive team at Selux Diagnostics has a history in cell technologies, senior science, postdoctoral fellowships, finance, and general management. They have been educated at Yale University, Harvard University, Merrimack College, and the University of New Hampshire - Whittemore School of Business and Economics.

CEO and Executive Team

Leadership Team

Founding Team

CEO and Executive Team

About

Team members

Other teams at Selux Diagnostics

Leadership Team

Founding Team